(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/208105 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07K 16/18* (2006.01)
A61P 35/00 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2025/022160

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/571,754 29 March 2024 (29.03.2024) US
63/714,650 31 October 2024 (31.10.2024) US

(71) Applicant: **PYXIS ONCOLOGY, INC.** [US/US]; 321 Harrison Avenue, 11th Floor, Suite 1, Boston, Massachusetts 02118 (US).

(72) Inventors: **SEVERE, Nicolas**; c/o Pyxis Oncology, Inc., 321 Harrison Avenue, 11 Floor, Suite 1, Boston, Pennsylvania 02118 (US). **PINKAS, Jan**; c/o Pyxis Oncology, Inc., 321 Harrison Avenue, 11 Floor, Suite 1, Boston, Pennsylvania 02118 (US). **HOLLANDER, Sara Lewandowski**; c/o Pyxis Oncology, Inc., 321 Harrison Avenue, 11 Floor, Suite 1, Boston, Pennsylvania 02118 (US). **DIAO, Liyang**; c/o Pyxis Oncology, Inc., 321 Harrison Avenue, 11 Floor, Suite 1, Boston, Pennsylvania 02118 (US).

(74) Agent: **SILVA, Domingos J.** et al.; Saul Ewing LLP, 1200 Liberty Ridge Drive, Suite 200, Wayne, Pennsylvania 19087 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CONSTRUCTS, COMPOSITIONS, AND METHODS FOR TREATING EXTRA DOMAIN B SPLICE VARIANT OF FIBRONECTIN-EXPRESSING DISEASES AND DISORDERS




FIG. 1

(57) Abstract: The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the cancer is selected from the group consisting of ER+HR+Her2-breast cancer, triple negative breast cancer (TNBC), head and neck cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, renal cancer, soft tissue sarcoma (sarcoma), and thyroid cancer.

[Continued on next page]

WO 2025/208105 A1

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*